Current management of neuroblastoma and future direction
- 1 April 2019
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 138, 38-43
- https://doi.org/10.1016/j.critrevonc.2019.03.013
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionCancer Discovery, 2013
- Promising Therapeutic Targets in NeuroblastomaClinical Cancer Research, 2012
- NeuroblastomaSeminars in Pediatric Surgery, 2012
- Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastomaBlood, 2011
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences of the United States of America, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaThe New England Journal of Medicine, 2010
- Recent Advances in NeuroblastomaThe New England Journal of Medicine, 2010
- Therapeutic Targeting of MycGenes & Cancer, 2010
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in NeuroblastomaCancer Research, 2008